Zynerba Press Releases

27 Jun 16 Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures

1 Jun 16 Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences

12 May 16 Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights

12 Apr 16 Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid

14 Mar 16 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights

7 Mar 16 Zynerba Pharmaceuticals to Present at 28th Annual ROTH Conference

25 Feb 16 Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome

6 Jan 16 Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial

24 Nov 15 Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences

16 Nov 15 Zynerba Pharmaceuticals Appoints Warren D. Cooper Lead Independent Director